Evercore ISI raised the firm’s price target on Regeneron (REGN) to $875 from $750 and keeps an Outperform rating on the shares. Regeneron is “looking strong with a refreshed outlook” and recent price hikes, argues the analyst. The company’s growth prospects are “particularly buoyed” by Dupixent and Eylea HD, which are positioned well to compete in the market, the analyst tells investors.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Explores New Intralesional Use for Libtayo in Skin Cancer: What Investors Should Know
- Regeneron Pharmaceuticals: Dupixent-Driven Growth Offset by Patent Uncertainty, Supporting a Hold Rating
- Regeneron Advances Early-Stage Eye Drug Pozelimab in Geographic Atrophy Trial
- Sanofi and Regeneron Withdraw Pediatric Dupilumab Growth Study: What Investors Should Know
- Regeneron Ends Phase 2 Heart Failure Trial for REGN5381: What Investors Should Know